Allurion Technologies merger with Compute Health Acquisition
We advised the capital markets adviser on the de-SPAC transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
BMS $35 million investment in Immatics
We advised Immatics on the private placement of ordinary shares
Korro Bio $117 million private placement
The financing is expected to close immediately prior to the completion of Korro Bio’s merger with Frequency Therapeutics
Bausch + Lomb $1.75 billion financing for acquisition of certain Novartis assets
We are advising Bausch + Lomb on the financing
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Noile-Immune Biotech ¥3.1 billion global IPO
The shares are listed on the Tokyo Stock Exchange
IDEAYA Biosciences $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
ATI Physical Therapy $100 million convertibles offering and recapitalization
We advised an ad hoc group of term lenders in connection with the transaction
Editas Medicine $125 million follow-on offering
The stock is listed on the Nasdaq Global Select Market
Cutia Therapeutics HK$412.9 million IPO
We advised Cutia on its IPO and HKEX listing